UZOMA OSUCHUKWU: Open Payments
NPI 1063760411 · N LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$915 in 46 payments from 9 companies in 2025. Trend: 2023 $683 · 2024 $1,165 · 2025 $915
Food & beverage: $915
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $226 |
| E.R. Squibb & Sons, L.L.C. | 9 | $211 |
| Alkermes, Inc. | 6 | $158 |
| Otsuka America Pharmaceutical, Inc. | 7 | $151 |
| Janssen Pharmaceuticals, Inc | 2 | $46 |
| Lundbeck LLC | 3 | $46 |
| Neurocrine BioSciences, Inc. | 2 | $35 |
| Bausch Health US, LLC | 1 | $25 |
| ABBVIE INC. | 1 | $16 |
Products named: CAPLYTA, COBENFY, ARISTADA, REXULTI, INVEGA SUSTENNA, ABILIFY ASIMTUFII, INGREZZA, APLENZIN.
Industry payments across NV — which companies pay providers there.
